Elderly people with glioblastoma - Authors' reply

The Lancet Oncology

Volumn 13, Issue 8, 2012, Pages

  Wick, Wolfgang ^a   Weller, Michael ^b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; TEMOZOLOMIDE; TUMOR MARKER;

AGE; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CLINICAL DECISION MAKING; CLINICAL TRIAL (TOPIC); COMORBIDITY; DNA METHYLATION; ELDERLY CARE; GLIOBLASTOMA; HEALTH CARE QUALITY; HUMAN; KARNOFSKY PERFORMANCE STATUS; LETTER; MONOTHERAPY; PATIENT SELECTION; POPULATION RESEARCH; PRIORITY JOURNAL; RISK REDUCTION; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 84864326004     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(12)70333-9     Document Type: Letter

References (3)

1. Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009, 10:459-466.
2. Wick W, Platten M, Meisner C, et al. Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol 2012, 13:707-715.
3. Malmström A, Gronberg BH, Marosi C, et al. Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet Oncol (in press).